

Bri Biosciences Limited
騰盛博药生物科技有限公司

(A company incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock Code 股份代號: 2137)

NOTIFICATION LETTER 通知信函

Dear Shareholders⁽¹⁾,

April 28, 2023

Bri Biosciences Limited (the “Company”)

– Notification of publication of 2022 Environmental, Social and Governance Report of the Company (the “2022 ESG Report”)

The English and Chinese versions of the 2022 ESG Report of the Company are only available electronically on the Company’s website at www.briibio.com and Hong Kong Exchanges and Clearing Limited’s website at www.hkexnews.hk (the “HKEX website”). You may view and/or download the 2022 ESG Report by clicking “About Us” on the home page of the website of the Company, and selecting “2022 Environmental, Social and Governance Report” or by clicking the relevant title as appeared thereon the HKEX website. If you wish to receive the Company’s 2022 ESG Report in printed form, you may submit your request in written to the Hong Kong Branch Share Registrar of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post.

Should you have any queries relating to this notification letter, please call the telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully,
For and on behalf of
Bri Biosciences Limited
Dr. Zhi Hong
Chairman

Note: (1) This notification letter is addressed to “Shareholder” and “Non-registered Shareholder”, which means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive environmental, social and governance report. If you have sold or transferred your shares of the Company, please disregard this notification letter.

各位股東⁽¹⁾：

騰盛博药生物科技有限公司 (「本公司」)

– 本公司刊發2022環境、社會及管治報告 (「2022年ESG報告」) 之發佈通知

本公司中英文版本的2022年ESG報告僅以電子形式載於本公司網站(www.briibio.com)及香港交易及結算所有限公司網站(www.hkexnews.hk) (「香港交易所網站」)。閣下可透過點擊本公司網站主頁上的「關於我們」一欄，選擇「2022環境、社會及管治報告」或於香港交易所網站透過點擊相關顯示的標題以閱覽及／或下載2022年ESG報告。如閣下欲收取本公司2022年ESG報告的印刷本，閣下可郵寄書面申請至本公司香港股份過戶登記分處卓佳證券登記有限公司，地址為香港夏慤道16號遠東金融中心17樓。

閣下如就本通知信函有任何疑問，請於辦公時間內致電查詢熱線(852) 2980 1333，辦公時間為星期一至星期五 (香港公眾假期除外) 上午9時正至下午6時正。

代表
騰盛博药生物科技有限公司
主席
Zhi Hong博士
謹啟

2023年4月28日

附註：(1) 本通知信函乃向本公司之股東及非登記之股東 (指股份存放於中央結算及交收系統的人士或公司，並透過香港中央結算有限公司不時向本公司發出通知，希望收取環境、社會和管治報告) 發出。如果閣下已經出售或轉讓本公司的股票，請毋須理會本通知信函。